Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04357795 · ClinicalTrials.gov registry record · Phase 4
Effect of Cequa™ in Subjects With Dry Eye Disease
A Phase 4 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 4
- Development phase
- 135
- Enrollment target
NCT04357795 is a Phase 4 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 135 participants.
The verdict
NCT04357795, a Phase 4 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 135 participants
- Enrollment target
Study Summary
This is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.
Interventions
- DRUG CequaTM (Cyclosporine 0.09%) ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2020-06-29 |
| Est. Completion | 2022-06-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04357795
The ClinicalTrials.gov registry entry for NCT04357795 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CequaTM (Cyclosporine 0.09%) ophthalmic solution is the first listed.
NCT04357795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04357795 about?
NCT04357795 is a clinical study titled "Effect of Cequa™ in Subjects With Dry Eye Disease". This is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.
What is the current status of trial NCT04357795?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 135 participants. The study started on 2020-06-29. Estimated completion is 2022-06-24.
What interventions are being tested in trial NCT04357795?
The interventions under investigation include: CequaTM (Cyclosporine 0.09%) ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT04357795?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.